FDA Warns Peptide Partners Over Seven Unapproved Injectable Peptides

A coordinated FDA enforcement action against illicit peptide vendors has reached Sarasota, Florida-based Peptide Partners LLC, whose website was found distributing seven unapproved injectable drug products, including semaglutide, tirzepatide, and retatrutide, in direct violation of sections 301(d) and 505(a) of the FD&C Act. For QA directors and regulatory leads at licensed compounders and manufacturers, the letter sharpens the compliance boundary at a moment when GLP-1 enforcement scrutiny is intensifying across the sector.

FDA's Center for Drug Evaluation and Research (CDER) conducted the review in July 2026, identifying the products, marketed under trade-adjacent names such as "GLP-1 S," "GLP-2 T," and "GLP-3 Reta", as unapproved new drugs under 21 U.S.C. 355(a). Product labeling on the firm's website made therapeutic claims referencing bone health, metabolic function, and neuroprotection, establishing intended use as defined under 21 CFR 201.128. The letter also covered SS-31 (Elamipretide), Tesamorelin, Bremelanotide, and a Bacteriostatic Water reconstitution solution.

CDER's warning letter explicitly flags the public health dimension: injectable drug products bypass the body's primary defenses against toxins and microorganisms, creating direct risk of serious and life-threatening harm. The agency noted the review was part of its broader responsibility to protect the public from unsafe, ineffective, and poor-quality drugs, language that signals this action sits within a wider enforcement sweep rather than an isolated referral.

The letter was addressed to Zachary David Hoff and delivered via electronic mail with read/delivery receipt requested, reference number 735063, dated August 24, 2026. FDA warned that failure to adequately address the cited violations may result in seizure or injunction without further notice. A secondary address, Pirsek Technologies, 6776 Timberland Lane, Sarasota, was also listed on the correspondence, suggesting potential operational overlap under review.

Legitimate compounders operating under 503A or 503B frameworks should treat this enforcement pattern as a prompt to audit their own labeling, website claims, and interstate distribution records, particularly for any GLP-1 or peptide-class products where therapeutic intent language could inadvertently mirror the violations cited here.

The agency's next measurable checkpoint will be Peptide Partners LLC's formal written response, which FDA expects to address all cited violations with corrective timelines and resource commitments.

Source: FDA CDER via What's New: Drugs RSS Feed, September 1, 2026. Warning Letter Reference No. 735063, issued August 24, 2026.